European Committee for Treatment and Research in Multiple Sclerosis
The ECTRIMS PodcastEpisodes
Episodes of The ECTRIMS Podcast
Mark All
Search Episodes...
In a landscape where funding is increasingly difficult to obtain, the importance of conducting research that has the greatest impact has never been more important. In the case of women with MS, a large-scale scoping review,* conducted on behalf
The ECTRIMS Congress offers a valuable opportunity for young researchers to gain experience and exposure. Joonas Lehikoinen from Helsinki University Hospital and the University of Helsinki Neurocenter, along with Ahmed Abdelhak from the Univer
With the growing push towards taking a more personalised approach to the treatment and management of multiple sclerosis, it is important to understand the unique issues – both socially and clinically – that may arise among people of different e
Discussions are ongoing to change the way MS patients are diagnosed and treated. In this episode, Xavier Montalban, Chair of the International Advisory Committee on Clinical Trials in Multiple Sclerosis, which is leading the discussions, expla
Recent global epidemiological data show that approximately 70% of people diagnosed with multiple sclerosis are women. While this may tell us something about the mechanisms behind disease susceptibility, it also raises a number of unique challe
The MSMilan Patient Community Day was designed for people living with multiple sclerosis and related neurological diseases and their caregivers to stay updated and involved in the advancements being made on their journey towards managing their
Why do some people with multiple sclerosis (MS) continue to run marathons while others are in wheelchairs years after diagnosis? Genetics partly explains why. Scientists have identified the first genetic marker for MS severity, which could pave
Descriptors of multiple sclerosis are currently based on a combination of clinical and MRI features, and include clinically isolated syndrome, relapsing-remitting, secondary and primary progressive subtypes. Accumulating evidence suggests that
Two sessions at the 9th Joint ECTRIMS-ACTRIMS Meeting (MSMilan2023) focused on nursing. Nurses play a critical role throughout an MS patient's life. And in this episode, we discuss the changing role of MS nurses and the challenges they face, wi
Long term use of disease modifying treatments (DMTs) poses challenges in terms of safety and pharmacoeconomics, while preventing disability progression. As such, there is an ongoing debate on how long disease modifying treatments should be cont
Listen to Clare Walton with MS Society UK and host Brett Drummond discuss the key takeways unveiled on the second day of MSMilan2023.
ECTRIMS Lecturer Dr. Stephen Hauser deep dives into the most relevant insights from day one of MSMilan2023, with host Brett Drummond.
Multiple sclerosis (MS) treatments have been successfully added onto the World Health Organisation's Essential Medicines List (EML) in July 2023. Nick Rijke of the MS International Federation and Deanna Saylor of Johns Hopkins Hospital discuss
MS affects more women than men. Research on the reasons behind this, and if and how sex-specific processes may impact disease progression, and the symptoms experienced by women living with MS continue to expand. In this episode, Rhonda Voskuhl
The development of global databases that record and store large amounts of clinical data for people living with MS has made a significant difference to the MS research world. In this episode, we talk to Izanne Roos of the University of Melbou
A longitudinal study published in 2022 found that infection with the Epstein-Barr virus (EBV) dramatically increased the risk of developing multiple sclerosis, suggesting that MS is likely caused by EBV. In this episode, Professor Alberto Asche
Everyone with MS should have access to the treatment and care that they need. Yet in 70% of countries, people face huge challenges in accessing disease modifying therapies (DMTs). Nick Rijke with the MS International Federation and Deanna Saylo
Tomas Kalincik, Head of the Clinical Outcomes Research Unit at the University of Melbourne, and Maria Pia Sormani, Professor of Biostatistics at the University of Genoa, discuss the use of real-world data to compare disease-modifying treatments
Will Brown and Alasdair Coles from University of Cambridge discuss remyelination in multiple sclerosis and a promising clinical trial that they are currently involved in.
Tomas Kalincik, Head of the Clinical Outcomes Research Unit at the University of Melbourne, explains his research comparing hematopoietic stem cell transplantation (HSCT) with existing treatments in relapsing and progressive MS.
Tomas Kalincik, Head of the Clinical Outcomes Research Unit at the University of Melbourne, explains his research comparing hematopoietic stem cell transplantation (HSCT) with existing treatments in relapsing and progressive MS.
MS Patient Experts Jana Hlavacova with the European Multiple Sclerosis Platform Young People's Network and Helga Weiland, Vice Chair of MS South Africa discuss the involvement of people with MS in conducting research.
Dr. Brigit de Jong from Amsterdam UMC and Professor Alan Thompson from Queens Square Institute of Neurology in London discuss promising, new short-term research data for people with MS unveiled in October during ECTRIMS 2022.
Dr. Daniel Ontaneda from the Cleveland Clinic speaks about promising, new mid-term research data for people with MS unveiled during the October 2022 ECTRIMS Congress.
Join Podchaser to...
- Rate podcasts and episodes
- Follow podcasts and creators
- Create podcast and episode lists
- & much more
Unlock more with Podchaser Pro
- Audience Insights
- Contact Information
- Demographics
- Charts
- Sponsor History
- and More!
- Account
- Register
- Log In
- Find Friends
- Resources
- Help Center
- Blog
- API
Podchaser is the ultimate destination for podcast data, search, and discovery. Learn More
- © 2024 Podchaser, Inc.
- Privacy Policy
- Terms of Service
- Contact Us